Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival

JAMA Oncology

Volumn 2, Issue 5, 2016, Pages 625-632

  Douxfils, Jonathan ^a   Haguet, Hélène ^a   Mullier, François ^b   Chatelain, Christian ^b   Graux, Carlos ^b   Dogné, Jean Michel ^a  

^a University of Namur   (Belgium)

^b CHU UCL NAMUR   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85010695061     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.5932     Document Type: Review

References (52)

1. Gainor JF, Chabner BA. Ponatinib: Accelerated Disapproval. Oncologist. 2015;20(8):847-848.
2. US Food and Drug Administration. Approval package for Iclusig. 2013. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2013/203469Orig1s007, s008.pdf. Accessed October 18, 2014.
3. US Food and Drug Administration. Label information for Tasigna. 2014. http://www .accessdata.fda.gov/drugsatfda-docs/label/2014/022068s017lbl.pdf. Accessed November 11, 2014.
4. Quintás-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk. 2012;12(5):337-340.
5. Aichberger KJ, Herndlhofer S, Schernthaner GH, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011;86(7):533-539.
6. Levato L, Cantaffa R, Kropp MG, Magro D, Piro E, Molica S. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronicmyeloid leukemia: a single institution study. Eur J Haematol. 2013;90(6):531-532.
7. Gambacorti-Passerini C, Piazza R. Choosing the right TKI for chronicmyeloid leukemia: when the truth lies in "long-term" safety and efficacy. Am J Hematol. 2011;86(7):531-532.
8. US Food and Drug Administration. Label information for Gleevec. 2014. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/021588s040lbl.pdf. Accessed November 11, 2014.
9. US Food and Drug Administration. Label information for Sprycel. 2014. http://www .accessdata.fda.gov/drugsatfda-docs/label/2014/021986s014lbl.pdf. Accessed November 11, 2014.
10. Douxfils J, Dogné J-M, Haguet H, et al. Risk of vascular occlusive events associated with BCR-ABL TKIs: a systematic review and meta-analysis of randomized controlled trials. http://www.crd.york .ac.uk/PROSPERO/display-record.asp?ID =CRD42014014147. Accessed January 5, 2016.
11. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12.
12. Borenstein M, Hedges L, Higgins J, Rothstein H. Introduction toMeta-Analysis. Hoboken, NJ:Wiley; 2009.
13. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
14. Radich JP, Kopecky KJ, Appelbaum FR, et al. A randomized trial of dasatinib 100mg versus imatinib 400mg in newly diagnosed chronic-phase chronicmyeloid leukemia. Blood. 2012;120(19): 3898-3905.
15. Kantarjian H, Pasquini R, Lévy V, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer. 2009;115(18):4136-4147.
16. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronicmyeloid leukemia. N Engl J Med. 2010;362(24):2260-2270.
17. Hjorth-Hansen H, Stenke L, Söderlund S, et al; Nordic CML Study Group. Dasatinib induces fast and deep responses in newly diagnosed chronicmyeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006). Eur J Haematol. 2015;94(3):243-250.
18. Saglio G, Kim DW, Issaragrisil S, et al; ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronicmyeloid leukemia. N Engl J Med. 2010;362(24):2251-2259.
19. Hughes TP, Lipton JH, Spector N, et al. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. Blood. 2014;124(5):729-736.
20. Choi SY, Lee SE, Kim SH, et al. Nilotinib vs high-dose imatinib in early chronic phase CML patients who have suboptimal molecular responses to standard-dose imatinib: updated data from RE-NICE study. Presented at the 54th Annual Meeting and Exposition of the American Society of Hematology; December 8-11, 2012; Atlanta, GA.
21. Lipton J, Chuah C, Guerci-Bresler A, et al. EPIC: a phase 3 trial of ponatinib compared with imatinib in patients with newly diagnosed chronicmyeloid leukemia in chronic phase. J Clin Oncol. 2014;32(15): 7023.
22. Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronicmyeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30(28): 3486-3492.
23. Giles FJ, MauroMJ, Hong F, et al. Rates of peripheral arterial occlusive disease in patients with chronicmyeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia. 2013;27(6):1310-1315.
24. Cortes JE, Kim DW, Pinilla-Ibarz J, et al; PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783-1796.
25. Le Coutre P, Rea D, Abruzzese E, et al. Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst. 2011;103(17):1347-1348.
26. Yang EH, Watson KE, Herrmann J. Should vascular effects of newer treatments be addressed more completely? Future Oncol. 2015;11(14):1995-1998.
27. Groarke JD, Cheng S, Moslehi J. Cancer-drug discovery and cardiovascular surveillance. N Engl J Med. 2013;369(19):1779-1781.
28. LiW, Croce K, Steensma DP, McDermott DF, Ben-Yehuda O, Moslehi J. Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors. J AmColl Cardiol. 2015; 66(10):1160-1178.
29. Valent P, Hadzijusufovic E, Schernthaner G-H, Wolf D, Rea D, le Coutre P. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood. 2015;125(6):901-906.
30. Gambacorti-Passerini C, Cortes JE, Lipton JH, et al. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronicmyeloid leukemia. Am J Hematol. 2014;89(10):947-953.
31. Lassila M, Allen TJ, Cao Z, et al. Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24(5):935-942.
32. Victor VM, Pritchard JR, Gonzalez F, Baker T, Gozgit JM, Hodgson G. Comparative TKI profiling analyses to explore potential mechanisms of ponatinib-associated arterial thrombotic events. Presented at the 56th Annual Meeting and Exposition of the American Society of Hematology; December 6-9, 2014; San Francisco, CA.
33. BrecciaM, Muscaritoli M, Aversa Z, Mandelli F, Alimena G. Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronicmyelogenous leukemia patients responsive to treatment. J Clin Oncol. 2004;22(22):4653-4655.
34. Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125(17):2128-2137.
35. RasheedW, Flaim B, Seymour JF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronicmyeloid leukemia. Leuk Res. 2009;33(6):861-864.
36. Sano M, Saotome M, Urushida T, et al. Pulmonary arterial hypertension caused by treatment with dasatinib for chronicmyeloid leukemia: critical alert. Intern Med. 2012;51(17): 2337-2340.
37. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354(24):2531-2541.
38. Quintás-Cardama A, Kantarjian H, O'brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25(25):3908-3914.
39. KrauthMT, Herndlhofer S, Schmook MT, Mitterbauer-Hohendanner G, Schlögl E, Valent P. Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100mg or 50mg daily. Haematologica. 2011; 96(1):163-166.
40. Eskazan AE, Soysal T, Ongoren S, Gulturk E, Ferhanoglu B, Aydin Y. Pleural and pericardial effusions in chronicmyeloid leukemia patients receiving low-dose dasatinib therapy. Haematologica. 2011;96(3):e15.
41. Rea D, Mirault T, Cluzeau T, et al. Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronicmyeloid leukemia. Haematologica. 2014;99(7):1197-1203.
42. Hochhaus A, Hughes TP, Clark RE, et al. ENESTnd update: nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and the impact of early molecular response (EMR) and sokal risk at diagnosis on long-term outcomes. Blood. 2013;122(21):92.
43. Cortes J, Kantarjian H, Khoury HJ, et al. Long-term evaluation of vascular toxicity in patients with Ph+ leukemias treated with bosutinib. Presented at the 2014 ASCO Annual Meeting; May 30 to June 3, 2014; Chicago, IL.
44. Gambacorti-Passerini C, Kantarjian HM, Kim DW, et al. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol. 2015;90(9):755-768.
45. Knickerbocker R, Dorer DJ, Haluska F, et al. Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients. Presented at the 56th Annual Meeting and Exposition of the American Society of Hematology; December 6-9, 2014; San Francisco, CA.
46. Cortes J, MauroM, Steegmann JL, et al. Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: data from the FDA adverse event reporting system. Am J Hematol. 2015;90(4):E66-E72.
47. Larson RA, Kim DW, Jootar S, et al. ENESTnd 5-year (y) update: long-term outcomes of patients (pts) with chronicmyeloid leukemia in chronic phase (CML-CP) treatedwith frontline nilotinib (NIL) vs imatinib (IM). Presented at the ASCO annual meeting; May 30 to June 3, 2014; Chicago, IL.
48. Hughes T, White D. Which TKI? An embarrassment of riches for chronicmyeloid leukemia patients. Hematology Am Soc Hematol Educ Program. 2013;2013(1):168-175.
49. Baccarani M, Castagnetti F, Gugliotta G, Palandri F, Rosti G. Treatment recommendations for chronicmyeloid leukemia. Mediterr J Hematol Infect Dis. 2014;6(1):e2014005.
50. European Medicines Agency. European Medicines Agency recommends further measures to minimise risk of blood vessel blockagewith Iclusig. 2014. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2014/10/news-detail-002193.jsp&mid=WC0b01ac058004d5c1. Accessed December 16, 2014.
51. Rea D, Nicolini FE, TulliezM, et al. Dasatinib or nilotinib discontinuation in chronic phase (CP)-chronicmyeloid leukemia (CML) patients (pts) with durably undetectable BCR-ABL transcripts: Interim analysis of the STOP 2G-TKI study with a minimum follow-up of 12 months-on behalf of the French CML group filmc. Presented at the 56th ASH annual meeting and exposition; December 9, 2014; San Francisco, CA.
52. Mahon FX, Baccarani M, Mauro M, et al. Treatment-free remission (TFR) following nilotinib (NIL) in patients (pts) with chronicmyeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath. Presented at the 2014 ASCO annual meeting; May 30 to June 3, 2014; Chicago, IL.